Evidence map›Paper›PMID 42079663›Full record

ArticleFrontiers in immunology2026

Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an

Angelique Augustin, Blandine Avignon, Christophe Boetsch, Ekaterina Breous-Nystrom, Olaf Broders, Lauriane Cabon, Karen Dernick, Evelyne Durr, Miro Julian Eigenmann, Susanne Fischer and 32 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Angelique AugustinRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Blandine AvignonRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Christophe BoetschRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Ekaterina Breous-NystromRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Olaf BrodersRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.
Lauriane CabonRoche Institute of Human Biology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Karen DernickRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Evelyne DurrRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Miro Julian EigenmannRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Susanne FischerRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Nick FlinnRoche Early Development Safety, Roche Products Ltd., Welwyn Garden City, United Kingdom.
Regine GerardRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Anna Maria GiustiRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.
Nikolche GjorevskiRoche Institute of Human Biology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Hans Juergen GroteRoche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Fabian HäusermannRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Nina HobiAlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland.
Elisabeth HusarRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Laurent JuglairRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Simon Patrick KeiserRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.
Nino KeshelavaRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.
Stefan KustermannRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Celine Marban-DoranRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Estelle Marrer-BergerRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Iris Martinez QuetglasRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.
Virginie MicallefRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Ramona MatheisRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Daniela Ortiz FranyutiRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Liudmila PolonchukRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Giulia RaggiAlveoliX AG, Swiss Organs-on-Chip Innovation, Bern, Switzerland.
Andreas RollerRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Pamela RuffinerRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Salma SadokRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Tulun SaylanRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Nathalie SchaubRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Desirée SchubertRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Satyajit ShetageRoche Pharma Development, Regulatory, Roche Products Ltd., Welwyn Garden City, United Kingdom.
Nadine Stokar-RegenscheitRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Antje-Christine WalzRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
Tina WeinzierlRoche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.
Vincent WolowskiRoche Pharma Development, Data Sciences, F. Hoffmann-La Roche, Basel, Switzerland.
Christine ZihlmannRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The nonclinical development of T-cell receptor (TCR)-based therapeutics is uniquely challenged by the human-exclusive specificity of the peptide-HLA target, rendering conventional animal models unsuitable for safety assessment. To support first-in-human (FIH) studies in patients with solid tumors with the novel TCR-like T Cell Bispecific (TCB) antibody MAGE-A4-TCB, targeting the MAGE-A4 peptide presented by HLA-A*02:01 and engaging T-cells via the CD3ϵ chain, we implemented a comprehensive, prediction-independent safety strategy relying on New Approach Methodologies (NAMs). This approach utilized 21 human cellular systems, including 2D and 3D

Indexed as

Antibodies, BispecificReceptors, Antigen, T-CellT-LymphocytesAntigens, NeoplasmCD3 ComplexCell Line, TumorCoculture TechniquesFemaleHLA-A2 AntigenHumansTranslational Research, BiomedicalAntibodies, BispecificAntigens, NeoplasmCD3 ComplexHLA-A2 AntigenReceptors, Antigen, T-Cellfirst-in-human (FIH) dose predictionin vitro modelsMAGE-A4/HLA-A*02:01new approach methodologies (NAMs)nonclinical safety evaluationorganoidsTCR-like T cell bispecific (TCB)translational PKPD

Identifiers

PMID42079663
PMCPMC13133561

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.